Stock BCLI BRAINSTORM CELL THERAPEUTICS INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Brainstorm Cell Therapeutics Inc.

Equities

BCLI

US10501E2019

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-16 pm EDT 		5-day change 1st Jan Change
0.5271 USD -3.94% Intraday chart for Brainstorm Cell Therapeutics Inc. -9.51% +93.08%
Apr. 09 Brainstorm Cell Therapeutics Says FDA Agrees on Design of Phase 3B ALS Trial MT
Apr. 09 Transcript : Brainstorm Cell Therapeutics Inc. - Special Call

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
BrainStorm Cell Therapeutics Regains Compliance with NASDAQ Minimum Market Value Rule
PR
BrainStorm Cell Therapeutics Announces Agreement with FDA on a Special Protocol Assessment for Phase 3b Trial in ALS
AQ
BrainStorm Cell Therapeutics Announces Peer-reviewed Publication of Biomarker Data from NurOwn's® Phase 3 Clinical Trial in ALS
PR
Brainstorm Cell Therapeutics Says FDA Agrees on Design of Phase 3B ALS Trial
MT
Transcript : Brainstorm Cell Therapeutics Inc. - Special Call
BrainStorm Cell Therapeutics Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Phase 3b Trial in ALS
PR
BrainStorm Cell Therapeutics Inc. Announces Agreement with FDA on Special Protocol Assessment for Phase 3b Trial in ALS
CI
BrainStorm Cell Therapeutics to Provide Update on NurOwn Program
PR
Brainstorm Cell Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
BrainStorm Cell Therapeutics Announces Full Year 2023 Financial Results and Provides Corporate Update
PR
North American Morning Briefing : Stocks Set for -2-
DJ
BrainStorm Cell Therapeutics to Unveil Phase 3b NurOwn Trial Design at MDA Clinical and Scientific Conference
AQ
BrainStorm Cell Therapeutics to Unveil Phase 3b NurOwn® Trial Design at MDA Clinical and Scientific Conference
PR
BrainStorm Cell Therapeutics Submits Special Protocol Assessment Request to FDA for Phase 3b Trial of NurOwn in ALS
AQ
BrainStorm Cell Therapeutics Submits Special Protocol Assessment (SPA) Request to FDA for Phase 3b Trial of NurOwn® in ALS
PR
BrainStorm Cell Therapeutics Submits Special Protocol Assessment Request to FDA for Phase 3b Trial of NurOwn in ALS
CI
BrainStorm Cell Therapeutics to Present at European Life Sciences CEO Forum
PR
Levi & Korsinsky Notifies Brainstorm Cell Therapeutics Inc.(BCLI) Investors of a Class Action Lawsuit and Upcoming Deadline
PR
BCLI FINAL DEADLINE NOTICE: ROSEN, LEADING TRIAL ATTORNEYS, Encourages Brainstorm Cell Therapeutics Inc. Investors with Losses in Excess of $500K to Secure Counsel Before Important January 2 Deadline in Securities Class Action Filed by the Firm
BU
BCLI FINAL DEADLINE TUESDAY: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Brainstorm Cell Therapeutics Inc. Investors with Losses in Excess of $500K to Secure Counsel Before Important January 2 Deadline in Securities Class Action Filed by the Firm - BCLI
PR
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. BCLI Stock
  4. News Brainstorm Cell Therapeutics Inc.